This article is more than 5 years old. Information may no longer be current.
Home-based AMD perimeter shown accurate at detecting early CNV
Click Here to Manage Email Alerts
FORT LAUDERDALE, Fla. — The Foresee Home preferential hyperacuity perimeter has been shown to accurately detect early choroidal neovascularization in patients using the device at home without supervision, according to a researcher here.
Anat Loewenstein, MD, of the Tel Aviv Medical Center, presented at the Association for Research in Vision and Ophthalmology meeting the results of a study of 109 patients at risk for developing wet age-related macular degeneration who used the Foresee Home PHP.
According to Dr. Loewenstein, the study enrolled intermediate AMD and CNV patients at eight centers in Israel. The patients were given a standard tutorial and short training session and then began using the unsupervised home test. The patients were also given biomicroscopy and fluorescein angiography.
The results of the tests showed a sensitivity of 85% and specificity of 84% with 95% confidence intervals.
"The Foresee Home test distinguishes between intermediate AMD and CNV eyes with high specificity and sensitivity," she said.
In an interview with Ocular Surgery News, Dr. Loewenstein said, "These patients are scared to death of losing their vision, especially those who have already lost vision in one eye, so this gives them confidence that we can detect CNV early."
Seventeen patients were excluded due to early AMD or geographic atrophy, and one was excluded due to poor photographic quality, Dr. Loewenstein said.
According to company literature, the device is expected to be available in the U.S. in 2010.